Abstract
Survival rates for Hodgkin lymphoma (HL) have substantially improved during the past several decades. Using stage-adapted polychemotherapy regimens and innovative radiation techniques, 5-year progression-free survival (PFS) has reached almost 90 % in young patients. Since the median age at diagnosis is approximately 32 years, these excellent results account for the majority of patients. Unfortunately, this progress has not translated into a similar benefit for older patients, especially for advanced-stage disease. Survival rates for HL patients aged ≥60 years are significantly and disproportionately inferior compared with younger patient populations.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395
Horning SJ, Hoppe RT, Breslin S et al (2002) Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol 20:630–637
Radford JA, Rohatiner AZ, Ryder WD et al (2002) ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin’s disease. J Clin Oncol 20:2988–2994
Austin-Seymour MM, Hoppe RT, Cox RS et al (1984) Hodgkin’s disease in patients over sixty years old. Ann Intern Med 100:13–18
Engert A, Ballova V, Haverkamp H et al (2005) Hodgkin’s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin’s study group. J Clin Oncol 23:5052–5060
Weekes CD, Vose JM, Lynch JC et al (2002) Hodgkin’s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20:1087–1093
Enblad G, Glimelius B, Sundström C (1991) Treatment outcome in Hodgkin’s disease in patients above the age of 60: a population-based study. Ann Oncol 2:297–302
Erdkamp FL, Breed WP, Bosch LJ et al (1992) Hodgkin disease in the elderly. A registry-based analysis. Cancer 70:830–834
Evens AM, Sweetenham JW, Horning SJ (2008) Hodgkin lymphoma in older patients: an uncommon disease in need of study. Oncology (Williston Park, NY) 22:1369–1379
Stark GL, Wood KM, Jack F et al (2002) Hodgkin’s disease in the elderly: a population-based study. Br J Haematol 119:432–440
Proctor SJ, Rueffer JU, Angus B et al (2002) Hodgkin’s disease in the elderly: current status and future directions. Ann Oncol 13(Suppl 1):133–137
Hamlin PA (2007) Treatment of aggressive non-Hodgkin’s and Hodgkin’s lymphoma in older patients. Am Soc Clin Oncol 12:295–299
Hurria A, Gupta S, Zauderer M et al (2005) Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104:1998–2005
Parkin DM, Muir CS (1992) Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ 120:45–173
Taylor PR, Angus B, Owen JP et al (1998) Hodgkin’s disease: a population-adjusted clinical epidemiology study (PACE) of management at presentation. Northern Region Lymphoma Group. QJM 91:131–139
Miller T, LeBlanc M, Braziel R et al (2002) Was the bimodal age incidence of Hodgkin’s lymphoma a result of mistaken diagnosis of non-Hodgkin’s lymphoma? Blood 100(771a) (abstract 3048)
Evens AM, Antillon M, Aschebrook-Kilfoy B et al (2012) Racial disparities in Hodgkin’s lymphoma: a comprehensive population-based analysis. Ann Oncol 23:2128–2137
Mir R, Anderson J, Strauchen J et al (1993) Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B. Cancer 71:1857–1866
Roy P, Vaughan Hudson G, Vaughan Hudson B et al (2000) Long-term survival in Hodgkin’s disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries. Eur J Cancer 36:384–389
Landgren O, Algernon C, Axdorph U et al (2003) Hodgkin’s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88:438–444
Proctor SJ, White J, Jones GL (2005) An international approach to the treatment of Hodgkin’s disease in the elderly: launch of the SHIELD study programme. Eur J Haematol Suppl 66:63–67
Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 31(12):1502–1505
Evens AM, Helenowski I, Ramsdale E et al (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119:692–695
Jarrett RF, Stark GL, White J et al (2005) Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 106:2444–2451
Evens AM, Hong F, Gordon LI et al (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161:76–86
van Spronsen DJ, Janssen-Heijnen ML, Breed WP et al (1999) Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, 1993–1996. Ann Hematol 78:315–319
Levis A, Anselmo AP, Ambrosetti A et al (2004) VEPEMB in elderly Hodgkin’s lymphoma patients. Results from an intergruppo Italiano linfomi (IIL) study. Ann Oncol 15:123–128
Guinee VF, Giacco GG, Durand M et al (1991) The prognosis of Hodgkin’s disease in older adults. J Clin Oncol 9:947–953
Levis A, Depaoli L, Urgesi A et al (1994) Probability of cure in elderly Hodgkin’s disease patients. Haematologica 79:46–54
Kim HK, Silver B, Li S et al (2003) Hodgkin’s disease in elderly patients (>or =60): clinical outcome and treatment strategies. Radiat Oncol Biol 56:556–560
Specht L, Nissen NI (1989) Hodgkin’s disease and age. Eur J Haematol 43:127–135
Ballova V, Ruffer JU, Haverkamp H et al (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin’s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly. Ann Oncol 16:124–131
Enblad G, Gustavsson A, Sundström C et al (2002) Patients above sixty years of age with Hodgkin’s lymphoma treated with a new strategy. Acta Oncol 41:659–667
Levis A, Depaoli L, Bertini M et al (1996) Results of a low aggressivity chemotherapy regimen (CVP/CEB) in elderly Hodgkin’s disease patients. Haematologica 81:450–456
Zinzani PL, Magagnoli M, Bendandi M et al (2000) Efficacy of the VBM regimen in the treatment of elderly patients with Hodgkin’s disease. Haematologica 85:729–732
Macpherson N, Klasa RJ, Gascoyne R et al (2002) Treatment of elderly Hodgkin’s lymphoma patients with a novel 5-drug regimen (ODBEP): a phase II study. Leuk Lymphoma 43:1395–1402
Martin WG (2005) Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin’s lymphoma. J Clin Oncol 23:7614–7620
Adach K, Suzuki M, Sugimoto T et al (2002) Granulocyte colony-stimulating factor exacerbates the acute lung injury and pulmonary fibrosis induced by intratracheal administration of bleomycin in rats. Exp Toxicol Pathol 53:501–510
Azoulay E, Herigault S, Levame M et al (2003) Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med 31:1442–1448
Matthews JH (1993) Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin’s disease: possible synergy. Lancet 342:988
Böll B, Görgen H, Fuchs M et al (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. J Clin Oncol 31:1522–1529
Klimm B, Eich HT, Haverkamp H et al (2007) Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin’s lymphoma: an analysis from the German Hodgkin Study Group. Ann Oncol 18:357–363
Landgren O (2006) A population-based cohort study on early-stage Hodgkin lymphoma treated with radiotherapy alone: with special reference to older patients. Ann Oncol 17:1290–1295
Kolstad A, Nome O, Delabie J et al (2007) Standard CHOP-21 as first line therapy for elderly patients with Hodgkin’s lymphoma. Leuk Lymphoma 48:570–576
Hagemeister FB (2007) Hodgkin’s lymphoma in younger patients: lessons learned on the road to success. Oncol (Williston Park, NY) 21:434–440; discussion 441–442– 445–446
Engert A, Diehl V, Franklin J et al (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin’s lymphoma: 10 years of follow-up of the GHSG HD9 study. J Clin Oncol 27:4548–4554
Walker A, Schoenfeld ER, Lowman JT et al (1990) Survival of the older patient compared with the younger patient with Hodgkin’s disease. Influence of histologic type, staging, and treatment. Cancer 65:1635–1640
Halbsguth TV, Nogova L, Mueller H et al (2010) Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood 116:2026–2032
Böll B, Bredenfeld H, Görgen H et al (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118:6292–6298
Proctor SJ, Wilkinson J, Jones G et al (2012) Prospective evaluation of treatment outcome in 175 patients with Hodgkin Lymphoma (HL) aged sixty years or over: the SHIELD study. Blood 119:6005–6015
Levis A, Merli F, Tamiazzo S et al (2007) ABVD versus VEPEMB in elderly hodgkin’s lymphoma patients. Blood 110:Abstract 2322
Canellos GP, Duggan D, Johnson J et al (2004) How important is bleomycin in the adriamycin + bleomycin + vinblastine + dacarbazine regimen? J Clin Oncol 22:1532–1533
Gallamini A, Hutchings M, Rigacci L et al (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752
Hutchings M, Loft A, Hansen M et al (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59
Younes A, Gopal AK, Smith SE et al (2012) Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol 30:2183–2189
Johnston PB, Inwards DJ, Colgan JP et al (2010) A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am J Hematol 85:320–324
Fehniger TA, Larson S, Trinkaus K et al (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 118:5119–5125
Lennard AL, Carey PJ, Jackson GH et al (1990) An effective oral combination in advanced relapsed Hodgkin’s disease prednisolone, etoposide, chlorambucil and CCNU. Cancer Chemother Pharmacol 26:301–305
Böll B, Goergen H, Arndt N et al (2013) Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin study group. J Clin Oncol 31:4431–4437
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing
About this chapter
Cite this chapter
Böll, B., Evens, A.M. (2015). The Management of Older Patients with Hodgkin Lymphoma. In: Engert, A., Younes, A. (eds) Hodgkin Lymphoma. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-12505-3_15
Download citation
DOI: https://doi.org/10.1007/978-3-319-12505-3_15
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-12504-6
Online ISBN: 978-3-319-12505-3
eBook Packages: MedicineMedicine (R0)